Numinus Wellness (NUMI) Stock Overview

Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies. The Canadian Clinic Network segment provides clinical services, including traditional therapy and counseling, ketamine-assisted therapies for depression, psychedelic-assisted therapies, mindfulness programs, and virtual psychotherapy services, as well as neurological care services. The US clinic network segment offers psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management services. The company also offers laboratory services, such as the cultivation, production, and extraction of natural Psilocybe and other psychoactive fungi species, the development of proprietary processes and products, methods for controlled psychedelics and development of a pipeline for product development, and protocol development and safety and efficacy studies; lab testing services; and psychedelic-assisted therapy training services. The company was incorporated in 1964 and is headquartered in Vancouver, Canada.